With in-house expertise, modern lab facilities and well-established partnerships, our scientists are developing unique and patented, world class technology. We utilize our technological platform to manufacture recombinant mucins for the development of natural eye care products.
Mucins are heavily glycosylated proteins, naturally occurring in tear fluid where they form an integral part of the eye’s defense against infections, lubricate and help keep the tear film intact. Natural properties include high wettability, low friction and the ability to coat and protect the cells of the eye, which make them ideal for eye care solutions.
We have the potential to develop the first available treatment of virally caused eye infection and to overcome the discomfort of dry eye disease and related contact lens discomfort by developing the next generation of eye care products for improved quality of life. We focus on development of tear substitutes, treatment and prevention of viral conjunctivitis and coating of contact lenses.
Eye care is one of the fastest growing specialty therapeutic areas today, driven by the increase in age-related eye diseases, the rise of emerging markets and by the development of novel therapies. We are addressing a rapidly growing market with a great and unmet need for improved eye care products.